没有走过的道路:错误地将抗发作药物归类为失败
Christopher N Henry1, Daniel M Goldenholz2,3
1Department of Neurology, Children's Hospital of Richmond at VCU Health, Virginia, United States.
Annals of clinical and translational neurology
|July 22, 2025
概括
发作频率的变化可能会错误地分类抗发作药物 (ASM) 的有效性. 许多看起来病情恶化或没有反应的患者实际上可能从ASM中受益,这凸显了在治疗中需要谨慎解释的必要性.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 抗发作药物 (ASM) 对于管理至关重要.
- 由于发作频率 (SF) 的自然波动,解释治疗反应可能具有挑战性.
研究的目的:
- 在考虑SF可变性时量化ASM有效性的错误分类.
- 为了确定ASM在看似无效的情况下提供好处的频率.
主要方法:
- 使用巧克力发作日记模拟器生成了10万名患者的发作日记.
- 模拟的药物效应为20%的平均SF减少,标准偏差为10%.
- 分析了明显恶化和反应率与真正的药物效益相比.
主要成果:
- 模拟反映了现实世界的试验,ASM显示36%的SF中位数减少vs17%的安慰剂.
- 在接受ASM治疗的患者中,有35%的患者实现了≥50%的SF减少,而安慰剂治疗的患者则为20%.
- 76%的看似恶化的患者是真正的改善者;只有4%的情况真正恶化.
结论:
- SF的变化对ASM收益的分类产生了重大影响.
- 许多被标记为治疗失败的患者可能正在经历有意义的好处.
- 需要进一步的临床研究来完善治疗的治疗反应的解释.
相关概念视频
Seizures: Classification
598
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
598
Epilepsy and Seizures: Overview
284
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
284
Antiepileptic Drugs: Potassium Channel Activators
280
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
280
Antiepileptic Drugs: Sodium Channel Blockers
898
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
898
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
454
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
454
Antiepileptic Drugs: Glutamate Antagonists
519
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
519


